BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37937579)

  • 1. Natural Plant Products Mediated Prevention of Cancer Facilitated through Immune Suppression of Treg Cells.
    Mukherjee O; Rakshit S; Shanmugan G; Sarkar K
    Curr Top Med Chem; 2023; 23(30):2973-2986. PubMed ID: 37937579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory T cells as a new therapeutic target for atherosclerosis.
    Ou HX; Guo BB; Liu Q; Li YK; Yang Z; Feng WJ; Mo ZC
    Acta Pharmacol Sin; 2018 Aug; 39(8):1249-1258. PubMed ID: 29323337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional Diversities of Regulatory T Cells in the Context of Cancer Immunotherapy.
    Gao R; Shi GP; Wang J
    Front Immunol; 2022; 13():833667. PubMed ID: 35371055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of regulatory T cells in cancer immunity.
    Takeuchi Y; Nishikawa H
    Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced suppression of polyclonal CD8
    Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
    J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
    Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
    J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
    Revenko A; Carnevalli LS; Sinclair C; Johnson B; Peter A; Taylor M; Hettrick L; Chapman M; Klein S; Solanki A; Gattis D; Watt A; Hughes AM; Magiera L; Kar G; Ireland L; Mele DA; Sah V; Singh M; Walton J; Mairesse M; King M; Edbrooke M; Lyne P; Barry ST; Fawell S; Goldberg FW; MacLeod AR
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Providence of the CD25
    Chakraborty S; Bhattacharjee P; Panda AK; Kajal K; Bose S; Sa G
    Immunol Cell Biol; 2018 Nov; 96(10):1035-1048. PubMed ID: 29768737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of TLRs inhibits CD4+ regulatory T cell function and activates lymphocytes in human peripheral blood mononuclear cells.
    Voo KS; Bover L; Harline ML; Weng J; Sugimoto N; Liu YJ
    J Immunol; 2014 Jul; 193(2):627-34. PubMed ID: 24928999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of regulatory T cells to cancer: A review.
    Najafi M; Farhood B; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):7983-7993. PubMed ID: 30317612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
    Nishikawa H; Koyama S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy.
    Togashi Y; Shitara K; Nishikawa H
    Nat Rev Clin Oncol; 2019 Jun; 16(6):356-371. PubMed ID: 30705439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. <Editors' Choice> Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity.
    Kochin V; Nishikawa H
    Nagoya J Med Sci; 2019 Feb; 81(1):1-18. PubMed ID: 30962651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
    Ohue Y; Nishikawa H
    Cancer Sci; 2019 Jul; 110(7):2080-2089. PubMed ID: 31102428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FoxP3
    Saleh R; Elkord E
    Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging role of natural products in cancer immunotherapy.
    Dong S; Guo X; Han F; He Z; Wang Y
    Acta Pharm Sin B; 2022 Mar; 12(3):1163-1185. PubMed ID: 35530162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
    Kumar P; Saini S; Prabhakar BS
    Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors regulating apoptosis and homeostasis of CD4+ CD25(high) FOXP3+ regulatory T cells are new therapeutic targets.
    Yang XF
    Front Biosci; 2008 Jan; 13():1472-99. PubMed ID: 17981643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.